Adamas Pharmaceuticals Profit Margin

The latest profit margin for ADMS is -71.11% as of September 2021. That compares with -89.12% in the prior-year period — up 20.2% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Adamas Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, ADMS's profit margin moved from -89.12% to -71.11% — a 20.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adamas Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, ADMS currently prints -71.11% for profit margin, while the sector average sits near 9.48%. That is roughly 850.0% below the sector mean. Large gaps often invite a closer look at Adamas Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Adamas Pharmaceuticals converts resources into returns. At -71.11%, ADMS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -89.12% in the prior-year period — up 20.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ADMS's profit margin (-71.11%), review year-over-year change from -89.12%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.